Idenix Pharmaceuticals, Inc.

Corporate Headquarters
60 Hampshire Street
United States

Tel: 617-995-9800
Fax: 617-995-9801

Show jobs for this employer

About Idenix Pharmaceuticals, Inc.

Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by hepatitis C virus. Idenix is advancing a robust product pipeline in HCV treatment with programs in four different HCV drug classes. The company’s clinical candidates include IDX184, a liver-targeted nucleotide polymerase inhibitor, IDX320, a protease inhibitor and IDX375, a non-nucleoside polymerase inhibitor. Idenix also has a preclinical NS5A inhibitor program. Idenix believes that the future of HCV treatment will include novel combinations of direct-acting antivirals (DAAs) which could eliminate the need for interferon and/or ribavirin. The company’s goal is to develop low dose, once- or twice-daily agents with broad genotypic activity, a low potential for drug-drug interaction and that are designed for use in multiple combination regimens. With programs that span the major HCV drug classes, Idenix is well positioned to build a combination drug development strategy, both internally and with partners, to advance the future HCV paradigm.

234 articles about Idenix Pharmaceuticals, Inc.